George Eric Davis
Known title: EVP, General CounselCIK: 0001380710
Associated companies
Transaction History
| BMRN | ▼ Sell | Open Market | 17,557 | $1.2M | 9/2/2026 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 1,273 | $71K | 3/18/2026 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 7,177 | $420K | 3/16/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 14,570 | $0 | 3/16/2026 | View on chart |
| BMRN | ▼ Sell | Open Market | 26,061 | $1.6M | 2/26/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 6,177 | $0 | 2/25/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 6,675 | $0 | 2/25/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 2,372 | $0 | 2/25/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 12,940 | $0 | 3/17/2025 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 16,249 | $1.1M | 3/14/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 9,367 | $0 | 2/25/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 11,040 | $0 | 2/25/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 9,660 | $0 | 2/25/2025 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 40,850 | $2.6M | 5/28/2024 | View on chart |
| BMRN | ▼ Sell | Open Market | 38,071 | $2.8M | 5/28/2024 | View on chart |
| BMRN | ▼ Sell | Open Market | 2,779 | $209K | 5/28/2024 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 1,850 | $117K | 5/2/2024 | View on chart |
| BMRN | ▼ Sell | Open Market | 1,850 | $157K | 5/2/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 301 | $21K | 4/30/2024 | View on chart |
| BMRN | ▼ Sell | Open Market | 24,602 | $2.2M | 3/28/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 10,260 | $0 | 3/15/2024 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 21,699 | $1.8M | 3/15/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 6,284 | $0 | 2/27/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 9,063 | $0 | 2/27/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 20,840 | $0 | 2/27/2024 | View on chart |
| BMRN | ▼ Sell | Open Market | 13,764 | $1.3M | 12/13/2023 | View on chart |
| BMRN | ▼ Sell | Open Market | 11,000 | $984K | 8/8/2023 | View on chart |
| BMRN | ▼ Sell | Gift | 210 | $0 | 5/16/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 317 | $21K | 4/28/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 19,957 | $1.9M | 3/16/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 3,025 | $265K | 3/15/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 8,900 | $0 | 3/15/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 10,100 | $0 | 2/28/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 7,424 | $0 | 2/28/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 20,200 | $0 | 2/28/2023 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 1,474 | $100K | 2/24/2023 | View on chart |
| BMRN | ▼ Sell | Open Market | 3,690 | $355K | 8/9/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 47,526 | $3.2M | 8/9/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 47,526 | $4.6M | 8/9/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 7,398 | $666K | 7/8/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 15,347 | $575K | 5/2/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 15,347 | $1.2M | 5/2/2022 | View on chart |
| BMRN | ▲ Buy | Grant | 341 | $21K | 4/29/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 2,669 | $100K | 4/25/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 6,129 | $498K | 3/21/2022 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 1,252 | $101K | 3/16/2022 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 8,290 | $649K | 3/15/2022 | View on chart |
| BMRN | ▲ Buy | Grant | 11,040 | $0 | 3/15/2022 | View on chart |
| BMRN | ▲ Buy | Grant | 9,370 | $0 | 3/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership
BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.